Skip to main content
Livermore
Livermore
ZHEN

Maverick Capital

Superinvestor

Maverick Capital Ltd

SEC CIK
0000934639
Manager
Lee Ainslie
Style
Hedge fund
Latest filing
Aug 14, 2026

The latest 13F from Maverick Capital covers Q2 2026 (filed Aug 14, 2026): 177 long positions worth $11.1B. The top 10 holdings make up 43.7% of the portfolio, and the largest is NVIDIA Corp (NVDA) at 5.5%. Livermore has 25 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
84
Est. +$1.85B
Added
49
Est. +$1.87B
Reduced
40
Est. −$1.98B
Sold out
146
Est. −$1.50B

Top 5 holdings

Share of this quarter's portfolio value

  1. NVDANVIDIA Corp
    5.5%$611.6MHistory
  2. AMDAdvanced Micro Devices Inc
    5.1%$567.2MHistory
  3. ALABAstera Labs, Inc.
    4.7%$515.5MHistory
  4. INTCIntel Corp
    4.6%$512.3MHistory
  5. GOOGAlphabet Inc.
    4.6%$509.5MHistory

Share of portfolio

Top 5 holdings and the other 172 positions, by share of portfolio value

  1. NVDA5.5%
  2. AMD5.1%
  3. ALAB4.7%
  4. INTC4.6%
  5. GOOG4.6%
  6. Other 172 positions75.5%

Biggest buys

New and added positions, by estimated amount bought

  1. METAMeta Platforms, Inc.
    +$430.4MNewHistory
  2. DPCDPC Holdings PLC
    +$251.5MNewHistory
  3. SNOWSnowflake Inc.
    +$248.8MNewHistory
  4. GFLGFL Environmental Inc.
    +$233.7MAddedHistory
  5. INSMINSMED Inc
    +$229.3MNewHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. METAMeta Platforms, Inc.
    +3.88 pp0.0% → 3.9%History
  2. AMDAdvanced Micro Devices Inc
    +3.52 pp1.6% → 5.1%History
  3. ALABAstera Labs, Inc.
    +3.43 pp1.2% → 4.7%History
  4. INTCIntel Corp
    +3.09 pp1.5% → 4.6%History
  5. DPCDPC Holdings PLC
    +2.27 pp0.0% → 2.3%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. AMATApplied Materials Inc
    −$627.2MReducedHistory
  2. ASMLASML Holding NV
    −$512.1MReducedHistory
  3. AGXArgan Inc
    −$253.1MSold outHistory
  4. TSMTaiwan Semiconductor Manufacturing Co Ltd
    −$251.0MReducedHistory
  5. TECHBIO-TECHNE Corp
    −$226.4MReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. ASMLASML Holding NV
    −3.95 pp4.0% → <0.1%History
  2. AMATApplied Materials Inc
    −3.44 pp3.5% → <0.1%History
  3. AGXArgan Inc
    −2.94 pp2.9% → 0.0%History
  4. LINLinde PLC
    −2.46 pp2.5% → 0.0%History
  5. INFQInfleqtion, Inc.
    −2.28 pp2.3% → 0.0%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$11.1B
+$2.48B (+28.9%) vs. prior quarter
Positions
177
−62 vs. prior quarter
Top 10 concentration
43.7%
Top 10 as share of value
Turnover
35.3%
Q2 2026, one quarter
Average holding period
6.9 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $11.1B (Q2 2026)

Q1 2021: $10.7BQ2 2021: $10.6BQ3 2021: $9.07BQ4 2021: $8.28BQ1 2022: $5.58BQ2 2022: $3.99BQ3 2022: $4.43BQ4 2022: $4.11BQ1 2023: $3.89BQ2 2023: $4.69BQ3 2023: $4.28BQ4 2023: $4.85BQ1 2024: $5.16BQ2 2024: $5.27BQ3 2024: $5.13BQ4 2024: $5.55BQ1 2025: $5.55BQ2 2025: $6.51BQ3 2025: $7.47BQ4 2025: $9.31BQ1 2026: $8.60BQ2 2026: $11.1B
Q1 2021Q2 2026
13F filings of Maverick Capital by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 2026177$11.1BNVDAAMDALABvs. Q1 2026SEC
Q1 2026May 15, 2026239$8.60BNVDAAMZNTSMvs. Q4 2025SEC
Q4 2025Feb 13, 2026178$9.31BNVDAMSFTAMZNvs. Q3 2025SEC
Q3 2025Nov 14, 2025201$7.47BAMZNMSFTNVDAvs. Q2 2025SEC
Q2 2025Aug 14, 2025249$6.51BNVDAAMZNTSMvs. Q1 2025SEC
Q1 2025May 15, 2025232$5.55BAMZNNVDAPMvs. Q4 2024SEC
Q4 2024Feb 14, 2025224$5.55BAMZNNVDAMSFTvs. Q3 2024SEC
Q3 2024Nov 14, 2024229$5.13BNVDAAMZNMSFTvs. Q2 2024SEC
Q2 2024Aug 14, 2024267$5.27BCPNGAMZNMSFTvs. Q1 2024SEC
Q1 2024May 15, 2024403$5.16BCPNGAMZNNVDAvs. Q4 2023SEC
Q4 2023Feb 14, 2024344$4.85BCPNGAMZNPMvs. Q3 2023SEC
Q3 2023Nov 14, 2023298$4.28BCPNGMETAAMZNvs. Q2 2023SEC
Q2 2023Aug 14, 2023390$4.69BCPNGNVDAAMZNvs. Q1 2023SEC
Q1 2023May 15, 2023447$3.89BCPNGCRMMETAvs. Q4 2022SEC
Q4 2022Feb 16, 2023Amended375$4.11BCPNGMETATMUSvs. Q3 2022SEC
Q3 2022Nov 14, 2022343$4.43BCPNGTMUSAMZNvs. Q2 2022SEC
Q2 2022Aug 15, 2022210$3.99BCPNGAMZNTMUSvs. Q1 2022SEC
Q1 2022May 16, 2022Amended225$5.58BCPNGAMZNMSFTvs. Q4 2021SECSEC
Q4 2021Feb 14, 2022304$8.28BCPNGAMZNMSFTvs. Q3 2021SEC
Q3 2021Nov 15, 2021620$9.07BCPNGMSFTCNCvs. Q2 2021SEC
Q2 2021Aug 18, 2021Amended660$10.6BCPNGMSFTCNCvs. Q1 2021SEC
Q1 2021May 17, 2021685$10.7BCPNGMSFTAMZN–SEC

13D and 13G filings

Companies where Maverick Capital reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

2 companies, largest stake first.

Companies where Maverick Capital owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
IVVDInvivyd, Inc.13G/A6.70%19.0M shares−1.80 ppfrom 8.50%Feb 14, 20244 filingsFeb 13, 2026SEC
WVEWave Life Sciences, Inc.13G/A5.40%8.26M shares–Feb 14, 20224 filingsFeb 14, 2025SEC

Latest filings

52 filings on file made by Maverick Capital or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by Maverick Capital
CompanyFiled (ET)FormStakeChangeEvent dateFiling
INFQInfleqtion, Inc.May 26, 20267:11 PM ET13D/A3.60%8.07M shares−5.60 ppfrom 9.20%Below 5%May 21, 2026SEC
INFQInfleqtion, Inc.Feb 18, 20268:09 PM ET13D9.20%20.0M sharesNewFeb 13, 2026SEC
BTUPeabody Energy CorpFeb 13, 20264:10 PM ET13G/A3.30%4.07M shares−3.40 ppfrom 6.70%Below 5%Dec 31, 2025SEC
RCKTRocket Pharmaceuticals, Inc.Feb 13, 20264:10 PM ET13G/A2.30%2.51M shares−5.50 ppfrom 7.80%Below 5%Dec 31, 2025SEC
IVVDInvivyd, Inc.Feb 13, 20264:10 PM ET13G/A6.70%19.0M shares−1.80 ppfrom 8.50%Dec 31, 2025SEC
GUTSFractyl Health, Inc.Nov 14, 20254:30 PM ET13G/A3.10%4.25M shares–Below 5%Sep 30, 2025SEC
CRISCuris IncNov 14, 20254:30 PM ET13G/A0.40%49.6K shares−7.60 ppfrom 8.00%Below 5%Sep 30, 2025SEC
BTUPeabody Energy CorpNov 14, 20254:30 PM ET13G/A6.70%8.16M shares+1.20 ppfrom 5.50%Sep 30, 2025SEC
BTUPeabody Energy CorpSep 26, 20254:30 PM ET13G5.50%6.65M sharesNewSep 19, 2025SEC
RCKTRocket Pharmaceuticals, Inc.Aug 14, 20258:00 AM ET13G/A7.80%8.36M shares+2.60 ppfrom 5.20%Jun 30, 2025SEC
IVVDInvivyd, Inc.Aug 14, 20258:00 AM ET13G/A8.50%10.2M shares–Jun 30, 2025SEC
RCKTRocket Pharmaceuticals, Inc.Apr 14, 20255:10 PM ET13G5.20%5.55M sharesNewApr 7, 2025SEC
VRNAVerona Pharma plcFeb 14, 20254:15 PM ET13G/A3.80%25.0M shares–Below 5%Dec 31, 2024SEC
WVEWave Life Sciences, Inc.Feb 14, 20254:15 PM ET13G/A5.40%8.26M shares–Dec 31, 2024SEC
CRISCuris IncFeb 14, 20254:15 PM ET13G/A8.00%681.4K shares–Dec 31, 2024SEC
VRNAVerona Pharma plcNov 14, 202413GOld format–New–SEC
IVVDInvivyd, Inc.Nov 14, 202413G/AOld format–––SEC
GUTSFractyl Health, Inc.Nov 14, 202413GOld format–New–SEC
IVVDInvivyd, Inc.Feb 14, 202413GOld format–New–SEC
ATRAAtara Biotherapeutics, Inc.Feb 14, 202413G/AOld format–––SEC